Treatment of hypertension during pregnancy: a cohort of pregnancy episodes from the SIDIAP database, Catalonia, Spain

Other authors

[Gomez-Lumbreras A] Department of Pharmacotherapy, College of Pharmacy, University of Utah, SLC, UT, United States. [Vilaplana-Carnerero C] Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Plataforma SCReN, UIC IDIAPJGol, Barcelona, Spain. Departament de Medicina, Universitat de Barcelona (UB), Barcelona, Spain. [Lestón Vázquez M] Universitat Autònoma de Barcelona, Bellaterra, Spain. Àrea del Medicament i Servei de Farmàcia, Gerència d'Atenció Primària Barcelona Ciutat, Institut Català de la Salut (ICS), Barcelona, Spain. [Vedia Urgell C] Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Atenció Primària Maresme, Barcelona, Spain. [Morros R] Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Plataforma SCReN, UIC IDIAPJGol, Barcelona, Spain. Institut Català de la Salut (ICS), Barcelona, Spain. [Giner-Soriano M] Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain

IDIAP Jordi Gol

Publication date

2024-07-25T06:16:20Z

2024-07-25T06:16:20Z

2024-06-17



Abstract

Hipertensió, Agents antihipertensius, Resultat de l'embaràs


Hipertensión, Agentes antihipertensivos, Resultado del embarazo


Hypertension, Antihypertensive agents, Pregnancy outcome


Introduction: Hypertension during pregnancy is oneofthemostfrequentcauses of maternal and fetal morbimortality. Perinatal and maternal death and disability rates have decreased by 30%, but hypertension during pregnancy has increased by approximately 10% in the last 30years. This research aimed to describe the pharmacological treatment and pregnancy outcomes of pregnancies with hypertension. Methods: We carried out an observational cohort study from the Information System for the Development of Research in Primary Care (SIDIAP) database. Pregnancy episodes with hypertension (ICD-10 codes for hypertension, I10–I15 and O10–O16) were identified. Antihypertensives were classified according to the ATC WHO classification: β-blocking agents (BBs), calcium channel blockers (CCBs), agents acting on the renin-angiotensin system (RAS agents), diuretics, and antiadrenergic agents. Exposure was defined for hypertension in pregnancies with ≥2 prescriptions during the pregnancy episode. Descriptive statistics for diagnoses and treatments were calculated. Results: In total, 4,839 pregnancieswithhypertensiondiagnosisformedthestudy cohort. There were 1,944 (40.2%) pregnancies exposed to an antihypertensive medication. There were differences in mother’s age, BMI, and alcohol intake between pregnancies exposed to antihypertensive medications and those not exposed. BBs were the most used (n = 1,160 pregnancy episodes; 59.7%), followed by RAS agents (n = 825, 42.4%), and CCBs were the least used (n = 347, 17.8%). Discussion: Pregnancies involving hypertension were exposed to antihypertensive medications, mostly BBs. We conduct a study focused on RAS agent use during pregnancy and its outcomes in the offspring.


The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was conducted with a grant from IDIAPJGol (this study received funding from the eighth call for SIDIAP grants, 2018 (expedient number 4R18/188) and from the Health Department of the Generalitat de Catalunya in the call corresponding to 2021 for the granting of funding of the Strategic Plan for Research and Innovation in Health (PERIS) 2021–2024, modality Research Projects in Primary Care, expedient number SLT21/21/000068.

Document Type

Article


Published version

Language

English

Publisher

Frontiers Media

Related items

Frontiers in Pharmacology;15

https://doi.org/10.3389/fphar.2024.1346357

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

https://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)